Trial
NCT01101581
Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Non Hodgkin's Lymphoma
Intervention
Veltuzumab and 90Y-Epratuzumab Tetraxetan
Why stopped
No subjects enrolled
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-18